Cell Harvesting System Market to Reach US$15.5 Bn by 2032, Says Persistence Market Research

The global cell harvesting system market is on a dynamic growth trajectory, valued at US$ 6.9 billion in 2025 and projected to reach US$ 15.5 billion by 2032, expanding at a CAGR of 12.2% during the forecast period (2025-2032). Cell harvesting, the process of isolating and collecting target cells from growth media, is a foundational step in biologics manufacturing and regenerative medicine. Historically dependent on manual techniques such as centrifugation and depth filtration, the field has rapidly evolved through automation, robotics, and digital integration-enhancing reproducibility, efficiency, and scalability across pharmaceutical and biotechnology workflows.

This transformation is fueled by the growing demand for regenerative medicine, stem cell therapies, and personalized medicine, along with advancements in biomanufacturing technologies. Integration of artificial intelligence (AI), single-use technologies, and closed-system automation has reshaped the cell harvesting ecosystem, enabling consistent yields and improved process control. Among market segments, automated cell harvesters are expected to dominate with a 67.4% share in 2025, reflecting the growing emphasis on precision-driven, high-throughput systems. North America leads the global market with a projected 38.6% value share, attributed to its advanced biopharmaceutical infrastructure, robust R&D funding, and widespread adoption of innovative automation platforms.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34752

Key Highlights from the Report

• Automated systems to capture 67.4% share of the global market by 2025 due to superior efficiency and scalability.
• Growing demand for regenerative medicine and personalized therapies drives sustained global market growth.
• Continuous innovations in automated harvesting and filtration systems enhance process reliability and yield.
• Strategic collaborations and acquisitions among key players expand product portfolios and market reach.
• Biopharmaceutical applications expected to dominate in 2025, driven by advanced therapy and vaccine development.
• North America to lead globally with a 38.6% value share owing to strong R&D infrastructure and funding.

Market Segmentation
By Product Type

The automated cell harvesting systems segment is projected to maintain market dominance through 2032, accounting for approximately 67.4% of total revenue in 2025. This dominance arises from the systems' ability to streamline workflow, minimize human intervention, and deliver consistent, reproducible results. Automation reduces contamination risks, supports closed-system operations, and allows for scalable bioprocessing-critical in high-volume applications like vaccine production and monoclonal antibody manufacturing. The transition from manual centrifugation and depth filtration to automated centrifuges and tangential flow filtration (TFF) has improved operational throughput while cutting waste and time.

By contrast, manual cell harvesting systems continue to serve niche applications in smaller laboratories and early-stage R&D, where flexibility and lower initial costs remain priorities. However, with increasing regulatory scrutiny and a growing push for process standardization, many organizations are progressively upgrading to automated systems integrated with digital monitoring and data analytics to comply with evolving Good Manufacturing Practices (GMP).

By Application

The biopharmaceutical segment represents the largest application category, accounting for a significant share of market revenue in 2025. The increasing reliance on biologics-such as monoclonal antibodies, gene therapies, vaccines, and stem cell-based treatments-has amplified demand for efficient, scalable, and contamination-free harvesting systems. Automation ensures high-quality cell yields and minimizes batch variability, crucial in large-scale bioproduction. The rise in personalized medicine and cell-based therapeutics has further accelerated adoption, as advanced systems facilitate the consistent recovery of therapeutic cells with minimal loss and enhanced purity.

In addition, the academic and research segment continues to grow steadily, supported by government and institutional funding aimed at expanding regenerative medicine and cellular therapy research. Universities and research centers increasingly use modular and closed-system harvesters to improve process reproducibility in translational research and preclinical trials.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/cell-harvesting-system-market.asp

Regional Insights
North America

North America remains the undisputed leader in the global cell harvesting system market, accounting for a 38.6% value share in 2025. The region's dominance stems from its robust biopharmaceutical ecosystem, state-of-the-art R&D infrastructure, and extensive investment in regenerative medicine. The U.S. and Canada host major biotechnology hubs, fostering collaboration between academia and industry. According to the Association of University Technology, over 200 new drugs and vaccines were developed through academic-industry partnerships between 1996 and 2020, highlighting the region's innovation strength.

Government initiatives and funding programs such as the NIH's Regenerative Medicine Innovation Project and the FDA's Emerging Technology Program continue to encourage modernization of cell processing workflows. With more than 190 of the world's top 260 small biopharma firms based in the U.S., spending an average of $637,000 per R&D employee, North America is positioned to maintain technological leadership. The adoption of AI-driven process control, integration of single-use systems, and a strong emphasis on personalized medicine all contribute to sustained market expansion.

Europe

Europe stands out as a fast-growing regional market driven by supportive regulations, public funding, and industrial innovation. Regulatory clarity and proactive funding from agencies such as the Deutsche Forschungsgemeinschaft (DFG) have accelerated adoption of modern biomanufacturing technologies. The establishment of 11 new Collaborative Research Centres (CRCs) in 2023 underscores Europe's commitment to advanced biomedical research. Additionally, leading manufacturers are expanding production capacity, such as Novartis's RPP1-CC facility in Austria, which aims to produce 1.7 million litres of cell culture harvest annually using advanced automated systems.

Europe's focus on sustainable and high-efficiency bioprocessing aligns with the industry's transition toward automation and single-use technologies. This region's integration of robotics, process analytics, and AI-enhanced systems ensures competitive growth, making it a key contributor to global innovation in cell harvesting technologies.

Asia Pacific

The Asia Pacific region is emerging as a vital growth engine for the global cell harvesting system market, bolstered by government initiatives, expanding biotech infrastructure, and rising healthcare investments. Countries such as Japan, China, South Korea, and India are heavily investing in regenerative medicine and biomanufacturing. For instance, FUJIFILM Corporation's US$200 million investment in 2023 aimed to strengthen cell therapy CDMO capabilities across its Cellular Dynamics and Diosynth Biotechnologies subsidiaries.

The growing prevalence of chronic diseases and a rapidly aging population have spurred demand for advanced therapies in the region. Local academic and research institutions are increasingly adopting modular and automated systems to scale up cell-based treatments. Government programs promoting biomedical innovation-such as Japan's "Society 5.0" initiative and China's "Made in China 2025" strategy-further stimulate technological adoption. With expanding biotech hubs and lower operational costs, Asia Pacific is poised to experience the fastest CAGR globally over the forecast period.

Market Drivers

The primary driver of the global cell harvesting system market is the accelerating pace of automation and digitalization in biomanufacturing. Automation enhances scalability, minimizes contamination, and reduces variability-critical factors for producing high-quality biologics. The integration of single-use technologies has further optimized workflows by reducing downtime associated with cleaning and validation. For example, Thermo Fisher Scientific's DynaSpin Single-Use Centrifuge, launched in 2022, reduced filter use sixfold and waste by 70%, illustrating how innovation directly supports sustainable and efficient operations.

Collaborations like Cytiva and Kite's Sefia platform, launched in 2024, demonstrate how automated closed systems are transforming CAR-T therapy manufacturing. These innovations align with regulatory initiatives, improving compliance while increasing throughput. Moreover, advancements in tangential flow filtration (TFF) and continuous centrifugation are enabling real-time monitoring, cost reduction, and faster turnaround-key requirements in next-generation biologics production.

Market Restraints

Despite robust growth prospects, the market faces significant challenges related to high implementation costs and legacy infrastructure. Many established biopharmaceutical facilities continue to rely on manual harvesting due to pre-existing capital investments and operational familiarity. Transitioning to automated systems requires extensive process validation, qualification testing, and staff retraining, leading to longer adoption cycles.

The cost of advanced automated equipment, combined with integration challenges across legacy systems, remains a barrier-especially for small and mid-sized biotech firms. Furthermore, while regulatory agencies like the FDA and EMA endorse innovation, variability in adoption rates across regions limits economies of scale. This uneven transition from manual to automated processes continues to restrain market expansion, particularly in cost-sensitive and emerging economies.

Market Opportunities

The cell harvesting system market is rich with untapped opportunities, especially as automation, robotics, and smart bioprocessing technologies evolve. Recent innovations such as Rousselot and IamFluidics' dissolvable microcarrier (IN-AIR MICROFLUIDICSTM) have simplified adherent cell harvesting, supporting scalable manufacturing for biologics and cell therapies. Similarly, the AVISO CellCelector, a robotic arm-equipped device, offers automated, precision-based single-cell selection-revolutionizing reproducibility in advanced research settings.

Emerging technologies like 3D-printed microfluidic platforms and lab-on-a-chip (LOC) systems are expected to redefine continuous harvesting for stem cells and complex biologics. The integration of AI and machine learning (ML) in data monitoring enhances process optimization and predictive maintenance, ensuring higher yield and minimal waste. As regenerative medicine and personalized therapy adoption accelerate, opportunities abound in scaling production to meet growing global clinical and commercial demand.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34752

Company Insights

The global cell harvesting system market is highly competitive, featuring established bioprocessing giants and emerging innovators focusing on automated solutions and integrated cell therapy manufacturing. Companies are investing heavily in R&D, partnerships, and mergers to enhance technological capabilities and global reach.

Key Players:

• Esco Micro Pte. Ltd.
• Sartorius AG
• Cytiva (Danaher)
• Technical Proteins Nanobiotechnology
• Beckman Coulter, Inc.
• Thermo Fisher Scientific Inc.
• Dr. Mueller AG
• Corning Incorporated
• PerkinElmer (Revvity)
• Smart MCs PTY LTD
• CARR Biosystems
• ScaleReady USA
• SINFONIA TECHNOLOGY CO., LTD.
• Cole-Parmer Instrument Company, LLC
• Human Med
• ADS Biotec Inc.
• Akadeum Life Sciences
• AVITA Medical
• Tomtec

Market Segmentation

By Product

Manual Cell Harvesters
Automated Cell Harvesters

By Application

Biopharmaceutical Applications
Cell Therapy
Tissue Engineering
Clinical Research & Trials
Others

By End-user

Hospitals
Biotech & Biopharma Companies
Academic & Research Institutes
Diagnostic Labs
Others

By Region

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa

Recent Developments:

Sphere Fluidics (June 2025): Launched Cyto?Mine Chroma, a next-generation single-cell analysis platform that integrates fluorescence multiplexing for rapid, automated isolation and harvesting of live cells, streamlining biopharmaceutical R&D workflows.

Ori Biotech Ltd. (December 2024): Partnered with Fresenius Kabi to merge the IRO® platform with Cue® and Lovo® cell processing systems, creating a unified, closed-loop manufacturing solution for cell therapy production.

These developments underscore the industry's transition toward integrated, automated, and digitally connected platforms aimed at improving reproducibility, throughput, and compliance with evolving GMP standards.

Conclusion

The global cell harvesting system market stands at the forefront of the biomanufacturing revolution, driven by automation, innovation, and the global demand for cell-based therapies. From manual centrifugation to AI-enabled closed systems, technological evolution is transforming cell processing into a data-driven, high-precision discipline. Automated harvesters are expected to lead market growth, supported by rising investment in regenerative medicine and personalized healthcare solutions.

While challenges persist-particularly around high system costs and uneven regional adoption-the ongoing shift toward digitalized, sustainable, and integrated workflows will unlock new opportunities across research, clinical, and commercial bioproduction. With North America leading today and Asia Pacific rapidly ascending, the cell harvesting system market is poised for a decade of profound expansion, reshaping the global landscape of biologics manufacturing and regenerative medicine.

Read More Related Reports:

Immuno-Oncology Market https://www.persistencemarketresearch.com/market-research/immunooncology-market.asp
Infectious Diseases Diagnostics Market https://www.persistencemarketresearch.com/market-research/infectious-diseases-diagnostics-market.asp
Medical Image Exchange Systems Market https://www.persistencemarketresearch.com/market-research/medical-image-exchange-systems-market.asp
ePRO, E-patient Diaries and eCOA Market https://www.persistencemarketresearch.com/market-research/epro-epatient-diaries-and-ecoa-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.